<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00082719</url>
  </required_header>
  <id_info>
    <org_study_id>ID03-0172</org_study_id>
    <secondary_id>P50CA091846</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>MDA-ID-030172</secondary_id>
    <secondary_id>CDR0000355831</secondary_id>
    <secondary_id>NCI-2012-02015</secondary_id>
    <nct_id>NCT00082719</nct_id>
  </id_info>
  <brief_title>Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium</brief_title>
  <official_title>Modulation of Death Effector Expression By Short-Term Exposure to Low-Dose Interferon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Interferon alfa may interfere with the growth of tumor cells and slow the growth
      of urothelial cancer.

      PURPOSE: This randomized phase I trial is studying how well low-dose interferon alfa works in
      treating patients with cancer of the urothelium.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the modulation of apoptosis-related pathways in patients with cancer of the
           urothelium treated with short-term low-dose interferon alfa.

      OUTLINE: This is a randomized study. Patients are randomized to 1 of 4 treatment arms.

      In all arms, treatment begins at the time of the pre-operative visit and continues until the
      time of cystoscopy.

        -  Arm I: Patients receive low-dose interferon alfa subcutaneously (SC) twice daily.

        -  Arm II: Patients receive interferon alfa as in arm I at a higher dose.

        -  Arm III: Patients receive interferon alfa SC once daily.

        -  Arm IV: Patients receive interferon alfa as in arm III at a higher dose. In all arms,
           treatment continues in the absence of unacceptable toxicity.

      PROJECTED ACCRUAL: Approximately 30 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Descriptive Data on Expression of Death Effectors in Context of Low-dose Interferon</measure>
    <time_frame>2 Years</time_frame>
    <description>Data collection continues with treatment in absence of unacceptable toxicity.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Urethral Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low-dose interferon alfa subcutaneously (SC) twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interferon alfa as in arm I at a higher dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interferon alfa SC once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interferon alfa as in arm III at a higher dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Interferon Alfa</intervention_name>
    <description>In all arms, treatment begins at pre-operative visit and continues until cystoscopy.
Arm I: Low-dose interferon alfa subcutaneously (SC) twice daily. Arm II: Interferon alfa as in arm I at a higher dose. Arm III: Interferon alfa SC once daily. Arm IV: Interferon alfa as in arm III at a higher dose.</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_label>Arm IV</arm_group_label>
    <other_name>Interferon Alfa 2b</other_name>
    <other_name>Intron A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must have histologically proven urothelial cancer, known or suspected (e.g.
             by outside evaluation) to be muscle-invasive, and be scheduled for cystoscopy and
             transurethral biopsy as part of their routine evaluation at M. D. Anderson.

          2. Patients must understand the investigational nature of this study and provide written,
             informed consent.

        Exclusion Criteria:

          1. Patients who are pregnant or lactating are not eligible. Women of child-bearing
             potential must have a negative pregnancy test before starting therapy.

          2. Patients with current symptoms suggestive of clinically significant affective
             disorder.

          3. Patients taking more than physiologic replacement doses of corticosteroids are not
             eligible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashish M. Kamat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Official Website</description>
  </link>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2004</study_first_submitted>
  <study_first_submitted_qc>May 18, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2004</study_first_posted>
  <last_update_submitted>May 12, 2015</last_update_submitted>
  <last_update_submitted_qc>May 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II bladder cancer</keyword>
  <keyword>stage III bladder cancer</keyword>
  <keyword>stage IV bladder cancer</keyword>
  <keyword>localized transitional cell cancer of the renal pelvis and ureter</keyword>
  <keyword>regional transitional cell cancer of the renal pelvis and ureter</keyword>
  <keyword>metastatic transitional cell cancer of the renal pelvis and ureter</keyword>
  <keyword>anterior urethral cancer</keyword>
  <keyword>posterior urethral cancer</keyword>
  <keyword>urethral cancer associated with invasive bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Urethral Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

